View Future GrowthSNDL 과거 순이익 실적과거 기준 점검 0/6SNDL은 연평균 31.6%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 연평균 19.2%의 비율로 증가했습니다. 매출은 연평균 27.9%의 비율로 증가했습니다.핵심 정보31.63%순이익 성장률45.27%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률23.06%매출 성장률27.90%자기자본이익률-2.04%순이익률-2.34%최근 순이익 업데이트30 Jun 2026최근 과거 실적 업데이트Reported Earnings • Jul 28Second quarter 2026 earnings released: CA$0.03 loss per share (vs CA$0.011 profit in 2Q 2025)Second quarter 2026 results: CA$0.03 loss per share (down from CA$0.011 profit in 2Q 2025). Revenue: CA$235.8m (down 3.7% from 2Q 2025). Net loss: CA$7.82m (down 371% from profit in 2Q 2025). Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Pharmaceuticals industry in Canada.공고 • Jul 16SNDL Inc. to Report Q2, 2026 Results on Jul 28, 2026SNDL Inc. announced that they will report Q2, 2026 results Pre-Market on Jul 28, 2026Reported Earnings • May 01First quarter 2026 earnings released: CA$0.04 loss per share (vs CA$0.057 loss in 1Q 2025)First quarter 2026 results: CA$0.04 loss per share (improved from CA$0.057 loss in 1Q 2025). Revenue: CA$195.9m (down 4.4% from 1Q 2025). Net loss: CA$9.91m (loss narrowed 33% from 1Q 2025). Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Pharmaceuticals industry in Canada.공고 • Apr 16SNDL Inc. to Report Q1, 2026 Results on Apr 29, 2026SNDL Inc. announced that they will report Q1, 2026 results Pre-Market on Apr 29, 2026Reported Earnings • Mar 13Full year 2025 earnings released: CA$0.06 loss per share (vs CA$0.36 loss in FY 2024)Full year 2025 results: CA$0.06 loss per share (improved from CA$0.36 loss in FY 2024). Revenue: CA$946.4m (up 2.8% from FY 2024). Net loss: CA$15.8m (loss narrowed 83% from FY 2024). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada.공고 • Feb 20SNDL Inc. to Report Q4, 2025 Results on Mar 12, 2026SNDL Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 12, 2026모든 업데이트 보기Recent updatesReported Earnings • Jul 28Second quarter 2026 earnings released: CA$0.03 loss per share (vs CA$0.011 profit in 2Q 2025)Second quarter 2026 results: CA$0.03 loss per share (down from CA$0.011 profit in 2Q 2025). Revenue: CA$235.8m (down 3.7% from 2Q 2025). Net loss: CA$7.82m (down 371% from profit in 2Q 2025). Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Pharmaceuticals industry in Canada.공고 • Jul 16SNDL Inc. to Report Q2, 2026 Results on Jul 28, 2026SNDL Inc. announced that they will report Q2, 2026 results Pre-Market on Jul 28, 2026Recent Insider Transactions • May 03Independent Non-Executive Chairman recently bought CA$95k worth of stockOn the 1st of May, J. Mills bought around 50k shares on-market at roughly CA$1.89 per share. This transaction increased J.'s direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. J. has been a buyer over the last 12 months, purchasing a net total of CA$166k worth in shares.Reported Earnings • May 01First quarter 2026 earnings released: CA$0.04 loss per share (vs CA$0.057 loss in 1Q 2025)First quarter 2026 results: CA$0.04 loss per share (improved from CA$0.057 loss in 1Q 2025). Revenue: CA$195.9m (down 4.4% from 1Q 2025). Net loss: CA$9.91m (loss narrowed 33% from 1Q 2025). Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Pharmaceuticals industry in Canada.공고 • Apr 16SNDL Inc. to Report Q1, 2026 Results on Apr 29, 2026SNDL Inc. announced that they will report Q1, 2026 results Pre-Market on Apr 29, 2026공고 • Mar 31SNDL Inc. Announces Executive Changes for Cannabis SegmentSNDL Inc. announced on March 30, 2026 that Tyler Robson, President of Cannabis, has left the Company in order to pursue other opportunities. Ryan Hellard, SNDL’s current Chief Strategy Officer, will assume the role of Interim President of Cannabis. The Company wishes Mr. Robson success in his future endeavours.New Risk • Mar 15New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 13% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (CA$21m net loss in 2 years).New Risk • Mar 13New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: CA$16m Forecast net loss in 2 years: CA$21m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company.Reported Earnings • Mar 13Full year 2025 earnings released: CA$0.06 loss per share (vs CA$0.36 loss in FY 2024)Full year 2025 results: CA$0.06 loss per share (improved from CA$0.36 loss in FY 2024). Revenue: CA$946.4m (up 2.8% from FY 2024). Net loss: CA$15.8m (loss narrowed 83% from FY 2024). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada.공고 • Feb 20SNDL Inc. to Report Q4, 2025 Results on Mar 12, 2026SNDL Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 12, 2026Board Change • Feb 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Independent Director James Cannell was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공고 • Nov 22SNDL Inc. (NasdaqCM:SNDL) announces an Equity Buyback for 24,500,000 shares, for CAD 100 million.SNDL Inc. (NasdaqCM:SNDL) announces a share repurchase program. Under the program, the company will repurchase up to 24,500,000 common shares, representing 10% of its issued share capital for CAD 100 million. The purpose of the program is opportunistically return value to shareholders. All shares purchased pursuant to the Share Repurchase Program will be returned to treasury for cancellation. The program is valid till November 20, 2026.New Risk • Nov 17New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: CA$92m Forecast net loss in 1 year: CA$3.8m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company.Recent Insider Transactions • Nov 10Independent Non-Executive Chairman recently bought CA$72k worth of stockOn the 6th of November, J. Mills bought around 40k shares on-market at roughly CA$1.79 per share. This transaction increased J.'s direct individual holding by 40000x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was J.'s only on-market trade for the last 12 months.Reported Earnings • Nov 04Third quarter 2025 earnings released: CA$0.05 loss per share (vs CA$0.073 loss in 3Q 2024)Third quarter 2025 results: CA$0.05 loss per share (improved from CA$0.073 loss in 3Q 2024). Revenue: CA$244.2m (up 3.1% from 3Q 2024). Net loss: CA$13.3m (loss narrowed 31% from 3Q 2024). Revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada.공고 • Oct 16SNDL Inc. to Report Q3, 2025 Results on Nov 04, 2025SNDL Inc. announced that they will report Q3, 2025 results at 9:30 AM, US Eastern Standard Time on Nov 04, 2025Reported Earnings • Aug 01Second quarter 2025 earnings released: EPS: CA$0.01 (vs CA$0.022 loss in 2Q 2024)Second quarter 2025 results: EPS: CA$0.01 (up from CA$0.022 loss in 2Q 2024). Revenue: CA$244.8m (up 7.3% from 2Q 2024). Net income: CA$2.89m (up CA$8.66m from 2Q 2024). Profit margin: 1.2% (up from net loss in 2Q 2024). Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in Canada.공고 • Jul 11SNDL Inc. to Report Q2, 2025 Results on Jul 31, 2025SNDL Inc. announced that they will report Q2, 2025 results Pre-Market on Jul 31, 2025공고 • Jun 23SNDL Inc., Annual General Meeting, Jul 29, 2025SNDL Inc., Annual General Meeting, Jul 29, 2025.New Risk • May 14New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: CA$107m Forecast net loss in 1 year: CA$9.5m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risk Currently unprofitable and not forecast to become profitable next year (CA$9.5m net loss next year).Reported Earnings • May 02First quarter 2025 earnings released: CA$0.06 loss per share (vs CA$0.01 loss in 1Q 2024)First quarter 2025 results: CA$0.06 loss per share (further deteriorated from CA$0.01 loss in 1Q 2024). Revenue: CA$204.9m (up 3.6% from 1Q 2024). Net loss: CA$14.7m (loss widened 476% from 1Q 2024). Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in Canada.공고 • Apr 15SNDL Inc. to Report Q1, 2025 Results on May 01, 2025SNDL Inc. announced that they will report Q1, 2025 results Pre-Market on May 01, 2025매출 및 비용 세부 내역SNDL가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이CNSX:SNDL 매출, 비용 및 순이익 (CAD Millions)날짜매출순이익일반관리비연구개발비30 Jun 26928-22208031 Mar 26937-11210031 Dec 25946-16211030 Sep 25952-92216030 Jun 25944-98214031 Mar 25928-107219031 Dec 24920-95219030 Sep 24911-110225030 Jun 24912-113224031 Mar 24916-136228031 Dec 23909-168230030 Sep 23901-211221130 Jun 23894-287213231 Mar 23886-331196231 Dec 22712-335158230 Sep 22495-266124330 Jun 22278-15188231 Mar 2264-13060231 Dec 2156-22755230 Sep 2147-22850230 Jun 2146-31649131 Mar 2157-29645031 Dec 2061-20046030 Sep 2062-17059130 Jun 2077-18470131 Mar 2076-16480331 Dec 1964-14386230 Sep 1949-15672230 Jun 1921-8454231 Mar 191-7737031 Dec 180-6822028 Feb 180-1390양질의 수익: SNDL 은(는) 현재 수익성이 없습니다.이익 마진 증가: SNDL는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: SNDL는 수익성이 없지만 지난 5년 동안 연평균 31.6%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 SNDL의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: SNDL은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(96.7%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: SNDL는 현재 수익성이 없으므로 자본 수익률이 음수(-2.04%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/04 21:48종가2026/08/04 00:00수익2026/06/30연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스SNDL Inc.는 9명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Aaron GreyAlliance Global PartnersFrederico Yokota Choucair GomesATB CormarkDavid KideckelATB Cormark6명의 분석가 더 보기
Reported Earnings • Jul 28Second quarter 2026 earnings released: CA$0.03 loss per share (vs CA$0.011 profit in 2Q 2025)Second quarter 2026 results: CA$0.03 loss per share (down from CA$0.011 profit in 2Q 2025). Revenue: CA$235.8m (down 3.7% from 2Q 2025). Net loss: CA$7.82m (down 371% from profit in 2Q 2025). Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Pharmaceuticals industry in Canada.
공고 • Jul 16SNDL Inc. to Report Q2, 2026 Results on Jul 28, 2026SNDL Inc. announced that they will report Q2, 2026 results Pre-Market on Jul 28, 2026
Reported Earnings • May 01First quarter 2026 earnings released: CA$0.04 loss per share (vs CA$0.057 loss in 1Q 2025)First quarter 2026 results: CA$0.04 loss per share (improved from CA$0.057 loss in 1Q 2025). Revenue: CA$195.9m (down 4.4% from 1Q 2025). Net loss: CA$9.91m (loss narrowed 33% from 1Q 2025). Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Pharmaceuticals industry in Canada.
공고 • Apr 16SNDL Inc. to Report Q1, 2026 Results on Apr 29, 2026SNDL Inc. announced that they will report Q1, 2026 results Pre-Market on Apr 29, 2026
Reported Earnings • Mar 13Full year 2025 earnings released: CA$0.06 loss per share (vs CA$0.36 loss in FY 2024)Full year 2025 results: CA$0.06 loss per share (improved from CA$0.36 loss in FY 2024). Revenue: CA$946.4m (up 2.8% from FY 2024). Net loss: CA$15.8m (loss narrowed 83% from FY 2024). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada.
공고 • Feb 20SNDL Inc. to Report Q4, 2025 Results on Mar 12, 2026SNDL Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 12, 2026
Reported Earnings • Jul 28Second quarter 2026 earnings released: CA$0.03 loss per share (vs CA$0.011 profit in 2Q 2025)Second quarter 2026 results: CA$0.03 loss per share (down from CA$0.011 profit in 2Q 2025). Revenue: CA$235.8m (down 3.7% from 2Q 2025). Net loss: CA$7.82m (down 371% from profit in 2Q 2025). Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Pharmaceuticals industry in Canada.
공고 • Jul 16SNDL Inc. to Report Q2, 2026 Results on Jul 28, 2026SNDL Inc. announced that they will report Q2, 2026 results Pre-Market on Jul 28, 2026
Recent Insider Transactions • May 03Independent Non-Executive Chairman recently bought CA$95k worth of stockOn the 1st of May, J. Mills bought around 50k shares on-market at roughly CA$1.89 per share. This transaction increased J.'s direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. J. has been a buyer over the last 12 months, purchasing a net total of CA$166k worth in shares.
Reported Earnings • May 01First quarter 2026 earnings released: CA$0.04 loss per share (vs CA$0.057 loss in 1Q 2025)First quarter 2026 results: CA$0.04 loss per share (improved from CA$0.057 loss in 1Q 2025). Revenue: CA$195.9m (down 4.4% from 1Q 2025). Net loss: CA$9.91m (loss narrowed 33% from 1Q 2025). Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Pharmaceuticals industry in Canada.
공고 • Apr 16SNDL Inc. to Report Q1, 2026 Results on Apr 29, 2026SNDL Inc. announced that they will report Q1, 2026 results Pre-Market on Apr 29, 2026
공고 • Mar 31SNDL Inc. Announces Executive Changes for Cannabis SegmentSNDL Inc. announced on March 30, 2026 that Tyler Robson, President of Cannabis, has left the Company in order to pursue other opportunities. Ryan Hellard, SNDL’s current Chief Strategy Officer, will assume the role of Interim President of Cannabis. The Company wishes Mr. Robson success in his future endeavours.
New Risk • Mar 15New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 13% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (CA$21m net loss in 2 years).
New Risk • Mar 13New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: CA$16m Forecast net loss in 2 years: CA$21m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company.
Reported Earnings • Mar 13Full year 2025 earnings released: CA$0.06 loss per share (vs CA$0.36 loss in FY 2024)Full year 2025 results: CA$0.06 loss per share (improved from CA$0.36 loss in FY 2024). Revenue: CA$946.4m (up 2.8% from FY 2024). Net loss: CA$15.8m (loss narrowed 83% from FY 2024). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada.
공고 • Feb 20SNDL Inc. to Report Q4, 2025 Results on Mar 12, 2026SNDL Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 12, 2026
Board Change • Feb 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Independent Director James Cannell was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공고 • Nov 22SNDL Inc. (NasdaqCM:SNDL) announces an Equity Buyback for 24,500,000 shares, for CAD 100 million.SNDL Inc. (NasdaqCM:SNDL) announces a share repurchase program. Under the program, the company will repurchase up to 24,500,000 common shares, representing 10% of its issued share capital for CAD 100 million. The purpose of the program is opportunistically return value to shareholders. All shares purchased pursuant to the Share Repurchase Program will be returned to treasury for cancellation. The program is valid till November 20, 2026.
New Risk • Nov 17New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: CA$92m Forecast net loss in 1 year: CA$3.8m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company.
Recent Insider Transactions • Nov 10Independent Non-Executive Chairman recently bought CA$72k worth of stockOn the 6th of November, J. Mills bought around 40k shares on-market at roughly CA$1.79 per share. This transaction increased J.'s direct individual holding by 40000x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was J.'s only on-market trade for the last 12 months.
Reported Earnings • Nov 04Third quarter 2025 earnings released: CA$0.05 loss per share (vs CA$0.073 loss in 3Q 2024)Third quarter 2025 results: CA$0.05 loss per share (improved from CA$0.073 loss in 3Q 2024). Revenue: CA$244.2m (up 3.1% from 3Q 2024). Net loss: CA$13.3m (loss narrowed 31% from 3Q 2024). Revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada.
공고 • Oct 16SNDL Inc. to Report Q3, 2025 Results on Nov 04, 2025SNDL Inc. announced that they will report Q3, 2025 results at 9:30 AM, US Eastern Standard Time on Nov 04, 2025
Reported Earnings • Aug 01Second quarter 2025 earnings released: EPS: CA$0.01 (vs CA$0.022 loss in 2Q 2024)Second quarter 2025 results: EPS: CA$0.01 (up from CA$0.022 loss in 2Q 2024). Revenue: CA$244.8m (up 7.3% from 2Q 2024). Net income: CA$2.89m (up CA$8.66m from 2Q 2024). Profit margin: 1.2% (up from net loss in 2Q 2024). Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in Canada.
공고 • Jul 11SNDL Inc. to Report Q2, 2025 Results on Jul 31, 2025SNDL Inc. announced that they will report Q2, 2025 results Pre-Market on Jul 31, 2025
공고 • Jun 23SNDL Inc., Annual General Meeting, Jul 29, 2025SNDL Inc., Annual General Meeting, Jul 29, 2025.
New Risk • May 14New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: CA$107m Forecast net loss in 1 year: CA$9.5m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risk Currently unprofitable and not forecast to become profitable next year (CA$9.5m net loss next year).
Reported Earnings • May 02First quarter 2025 earnings released: CA$0.06 loss per share (vs CA$0.01 loss in 1Q 2024)First quarter 2025 results: CA$0.06 loss per share (further deteriorated from CA$0.01 loss in 1Q 2024). Revenue: CA$204.9m (up 3.6% from 1Q 2024). Net loss: CA$14.7m (loss widened 476% from 1Q 2024). Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in Canada.
공고 • Apr 15SNDL Inc. to Report Q1, 2025 Results on May 01, 2025SNDL Inc. announced that they will report Q1, 2025 results Pre-Market on May 01, 2025